In extrahepatic tissues lipoprotein lipase (LPL) hydrolyzes triglycerides thereby generating FFA for tissue uptake and metabolism. To study the effects of increased FFA uptake in muscle tissue, transgenic mouse lines were generated with a human LPL minigene driven by the promoter of the muscle creatine kinase gene. In these mice human LPL was expressed in skeletal muscle and cardiac muscle, but not in other tissues. In proportion to the level of LPL overexpression, decreased plasma triglyceride levels, elevated FFA uptake by muscle tissue, weight loss, and premature death were observed in three independent transgenic mouse lines. The animals developed a severe myopathy characterized by muscle fiber degeneration, fiber atrophy, glycogen storage, and extensive proliferation of mitochondria and peroxisomes. This degree of proliferation suggests that FFA play an important role in the biogenesis of these organelles. Our experiments indicate that LPL is rate limiting for the supply of muscle tissue with triglyceride-derived FFA. Improper regulation of muscle LPL can lead to major pathological changes and may be important in the pathogenesis of some human myopathies. Muscle-specific LPL transgenic mouse lines will serve as a useful animal model for the investigation of myopathies and the biogenesis of mitochondria and peroxisomes. (J. Clin. Invest. 1995. 96:976-986.)
Introduction
In all vertebrates lipoprotein lipase (LPL)l [E.C.3.1.1.34] is responsible for the hydrolysis of triglycerides from triglyceriderich lipoproteins (chylomicrons and VLDL) thereby supplying FFA for the subsequent uptake in extrahepatic tissues (1, 2).
The human LPL gene is located on chromosome 8p22 (3) . The major sites of LPL expression and enzymatic activity are muscle and adipose tissue. The enzyme is bound to the capillary endothelium probably by interaction with heparan sulfate. Hydrolysis of triglycerides by LPL is a prerequisite for the uptake of triglyceride-derived FFA by peripheral cells. Absence of the enzyme activity, as observed in patients affected with type I hyperlipoproteinemia, causes severe chylomicronemia and other metabolic complications (4) (5) (6) . After uptake, the intracellular metabolism of FFA is quite different in various tissues. In muscle FFA are mainly utilized for p-oxidation and energy production. In adipose tissue FFA are reesterified and deposited as lipid droplets for storage. In accordance with these distinct metabolic functions, the regulation of extracellular triglyceride lipolysis by LPL is different in adipose tissue and muscle (7) . For example, during fasting LPL activity is low in fat but high in muscle, whereas during refeeding it is high in fat but decreased in muscle. These tissue specific differences suggested a "gate keeping" function for LPL, which carefully balances the partitioning of triglyceride-derived FFA among different tissues (8) .
Although the uptake mechanism of EFA into cells is still obscure, we speculated that tissue specific overexpression of LPL in muscle might represent an experimental model to increase FFA in myocytes. This would allow the investigation of the metabolic effects of FFA in muscle tissue. Therefore, human LPL was specifically overexpressed in skeletal muscle and heart muscle of transgenic mice and the physiological consequences of this overexpression were studied with regard to lipid metabolism as well as the intracellular effects of FFA. In addition to a decrease in the plasma triglyceride levels of transgenic mice, overexpression of human LPL in skeletal and cardiac muscle caused a remarkable increase in the number of mitochondria and peroxisomes in muscle fibers and the development of myopathy which resulted in the premature death in all transgenic animals. All these effects were correlated directly with the level of LPL expression in muscle tissue. We hypothesize that dysfunctional regulation of triglyceride hydrolysis and FPA uptake in muscle might be important in the pathogenesis of some human myopathies.
Methods LPL-minigene construction. All cloning steps were performed according to well-established protocols (9) . A human LPL expression construction was assembled from different partial LPL cDNA clones (10) , a 1.3-kb fragment of the human gene containing 39 bp of exon 3, the complete intron 3 and 64 bp of exon 4. A 1093-bp DNA fragment containing 754 bp of the last exon, the polyadenylation signal, and 339 bp of gene flanking region was added to the 3' end. The LPL minigene was cloned into pBluescript. To isolate the regulatory sequences of the mouse cre-atine kinase gene ( 11) , p3300MCKCAT (gift of Dr. R Hauschka, University of Washington, Seattle, WA) was cut with PstI and BstEII. These restriction cleavages yielded a DNA fragment of 3307 bp of 5' flanking region. This fragment was subsequently cloned into pBluescript and fused with the LPL construction. The complete LPL-minigene, encompassing 8.5 kb of DNA, was prepared by cutting the plasmid with PstI and KpnI, isolating the linear DNA fragment by electroelution, and purifying it using a Elutip D column obtained from Schleicher & Schuell, Inc. (Dassel, Germany).
Generation oftransgenic mice. A linear piece of DNA encompassing the complete LPL minigene was injected into the male pronucleus of fertilized eggs from superovulated (C57B1/6J x CBA/J) F1 females that had been mated to males of the same genetic background (12) . Microinjected eggs were transferred into the oviducts of surrogate females. Founder animals were bred to (C57B1/6J x CBA/J)F1 animals and three transgenic mouse lines were established: low expression line (MCK-L), medium expression line (MCK-M), and high expression line (MCK-H).
DNA and RNA analysis. For Southern blotting 10 jig of tail tip DNA was digested with Pvul, fractionated by agarose gel electrophoresis, and blotted on nylon membranes. DNA corresponding to the human LPL minigene was detected with a radiolabeled 1.2-kb NcoI-EcoRI fragment from the human LPL cDNA. RNA isolation and blotting techniques were performed as described previously (13) . To differentiate human LPL mRNA from the endogenous mouse mRNA a species-specific DNA-probe containing a 1-kb EcoRI fragment from exon 10 of the human LPL gene was used. This DNA probe specifically detected the 3' untranslated region of the human LPL mRNA but did not cross react with the mouse mRNA.
Lipolytic enzymes. Postheparin plasma was taken 5 min after bolus injection of sodium heparin (100 U/kg) into the tail vein. The epididymal fat pads and heart and thigh muscle specimens (100 mg each) were surgically removed from the animals and put into ice-cold tubes containing 1 ml of DME medium with 2% BSA and 2 U/ml heparin. After mincing the tissue with scissors, it was incubated in medium for 1 h at 37°(. Enzyme activities of LPL in muscle tissue and adipose tissue as well as LPL and hepatic triglyceride lipase activity in postheparin plasma of transgenic mice were assayed as described earlier (14) . The assay of postheparin plasma was performed in the presence or absence of 1 M NaCl to estimate both the LPL and hepatic lipase activities. LPL activity was calculated as the portion of total lipase activity inhibited by 1 M NaCl. To differentiate between human and mouse LPL activity in tissue extracts or postheparnn plasma, the assay mixtures were preincubated for 1 h at 4°C in the presence of or absence of 0.1 g mAb 5D2 (kindly provided by Dr. J. D. Brunzell, University of Washington, Seattle, WA) (15) or 10 jA polyclonal antiserum prepared in our own laboratory (14) . These antibodies both specifically inhibit the human but not the mouse enzyme in LPL activity determinations. After enzyme inhibition, activity measurements proceeded as described above.
Plasma parameters. Control and transgenic animals were fed a regular mouse chow (4.5% fat, 21% protein). Mice were housed in plastic cages and given free access to food and water. Blood was taken from etherized mice after an overnight fasting period and plasma was immediately prepared. Total plasma cholesterol was determined by the CHOD-PAP method (Greiner Diagnostica, Vienna, Austria). Triglycerides were determined using an enzymatic kit from Sero-Merieux (Vienna, Austria Microscopy and cytochemistry. Immediately after decapitation fresh muscle specimens from the upper and lower foreleg and hindleg were prepared for light microscopical, histochemical, and ultrastructural analyses. For electronmicroscopy samples of the skeletal muscles, nervus ischiadicus, and myocardium were fixed in 4% phosphate-buffered glutaraldehyde (pH 7.2) for 4 h, postfixed with 1% OSO4 in sodium cacodylate buffer, dehydrated, and finally embedded in Epon 812. After screening toluidine blue-stained semi-thin sections by light microscopy, ultrathin sections were cut with an OmU4 Ultracut ultramicrotome (Reichert Jung, Vienna, Austria), stained with uranyl acetate and lead citrate, and examined with an EM 400 electron microscope (Philips Electronic Instruments Co.) at 80 kV. For histochemical investigations unfixed muscle specimens were frozen in 5-methylbutan (E. Merck) which was precooled in liquid nitrogen, and stored at -20°C until 4-,sm cryocut sections were stained with haematoxylin and eosin, myosin adenosine triphosphatase (ATPase after preincubation at pH 4.2, 4.6, and 9.4 for classifying fiber types), NADH tetrazolium reductase (NADH-TR, staining mitochondria, but also interfibrillary sarcoplasmatic tubules and reticulum), Gomori-trichrome (mitochondrial stain), and oil red-O (lipid staining) techniques. In addition to formalin-fixed (neutral phosphate-buffered 10% formaldehyde solution) specimens of the muscles and samples from other organs (e.g., the whole brain in frontal slices, the whole heart in transverse sections, lungs, liver, gastrointestinal tract, spleen, kidney, adrenal gland, and urogenital tract) were embedded in paraffin wax by conventional techniques and investigated in haematoxylin and eosin-, Masson-trichrome, and periodic acid Schiff (PAS) -stained sections. Cytochemical staining for intracellular catalase activity using diaminobenzidine for the visualization of peroxisomes was performed as described by Roels et al. ( 19) . The enzymatic activity of the mitochondrial marker enzyme succinate dehydrogenase was performed according to Peters et al. (20) . Catalase activity, as a marker for peroxisomes was measured as described by Pennington (21 Generation of transgenic mice. An LPL minigene was constructed containing the full-length human LPL cDNA (10) including the 5' untranslated sequence, the complete coding region, the 3' untranslated sequence, and 339 bp of 3' flanking region ( Fig. 1 A) . The coding region of this construction was interrupted by a single intron (intron 3 of the human LPL gene) as the presence of at least one intron has been demonstrated to increase the level of expression of transgenes (22) . The complete minigene was fused with a 3.3-kb piece of DNA containing the promoter region of the mouse muscle creatine kinase gene (kindly provided by Dr. S. D. Hauschka, University of Washington, Seattle, WA). This promoter has been successfully used in the highly tissue-specific overexpression of a reporter gene in skeletal muscle and heart muscle of transgenic mice ( 11). LPL-transgenic mice were generated as previously described (8) . Three transgenic mice were obtained as founders resulting in three independent lines (MCK-L, MCK-M, and MCK-H).
Transgene integration and expression. Semiquantitative Southern blotting ( Fig. 1 B) revealed that MCK-L had three copies of the LPL minigene integrated in its genome. MCK-M contained 10 copies and MCK-H integrated an estimated number of 20 copies per genome. LPL gene expression was measured by mRNA and enzyme activity levels. Using a speciesspecific probe, human LPL mRNA of the expected size (3.6 kb) was found in skeletal muscle and cardiac muscle of mice from all transgenic lines (Fig. 1 C) . The least amount of this transcript was detected in MCK-L, followed by MCK-M. MCK-H expressed the highest amount of human LPL-mRNA in muscle tissue. No human LPL mRNA was detected in adipose tissue or any other tissue except muscle, verifying the highly tissuespecific properties of the muscle creatine kinase promoter. As expected, no human LPL mRNA signal was detected in nontransgenic control mice indicating the specificity of the DNA probe.
The enzyme activities of endogenous mouse LPL and human LPL were analyzed in skeletal muscle, heart, and adipose tissue in all transgenic mouse lines as well as control mice (Table I) . Heparin releasable LPL activity in skeletal muscle exhibited a highly significant 5.5-fold increase of LPL activity in MCK-L, an 8.1-fold increase in MCK-M, and a 24.4-fold increase in MCK-H animals compared to the levels in control mice. A similar result, although less pronounced was obtained for heparin-releasable LPL activities in cardiac muscle, which was found to be increased by 20% in MCK-L, 55% in MCK-M and 221% in MCK-H over the endogenous mouse LPL activity. To differentiate the human from mouse LPL activity, a polyclonal antiserum or the monoclonal antibody 5D2 (a gift of Dr. J. Brunzell, University of Washington, Seattle, WA) directed against human LPL was used for the specific inhibition of the human enzyme ( 14, 15 (Fig. 3) . 2-moold MCK-H animals exhibited a massive loss of muscle mass as well as the virtually complete disappearance of adipose tissue (Fig. 3) , which accounted for the overall weight loss in these animals. The loss of adipose tissue was also confirmed by macroscopic pathological examination of five animals which showed that the epididymal fat pads were scarcely detectable.
Effects on muscle morphology. The "lipolysis induced" loss of muscle mass in transgenic mice was morphologically investigated by light microscopy, histochemical procedures, and electron microscopy of skeletal and heart muscle tissue in two male and two female animals of each line 8 wk after birth. Since the MCK-L and MCK-M animals did not show any pathologic changes within 8 wk, animals were also examined 5 mo post partum.
Light microscopically (Fig. 4) , skeletal muscle samples from 5-mo-old MCK-L animals were found to be identical compared to control animals (a and d). Similarly, samples from MCK-M animals exhibited no obvious myopathic changes at this age (b and e). In PAS-stained sections only a few fibers exhibited a low degree of glycogen storage in subsarcolemmic position. In contrast, in MCK-H animals a severe myopathy with fiber degeneration, fiber atrophy, lymphocytic, and mesenchymal reaction was already detectable within 2 mo of age (c and f). In only a few muscle fibers local glycogen storage was detected (e, arrow). In contrast, even at 2 mo of age severe myopathy was found in the MCK-H animals (c and f). This myopathy was characterized by excessive glycogen storage in muscle fibers (stained intensively red by PAS reaction in c and f ), muscle fiber degeneration, atrophy, lymphocytic, and mesenchymal reaction. Additionally, many centralized nuclei forming nuclear chains (f, arrows), which resemble myotubes, were detected in longitudinal sections of muscle fibers. a, b, c x1650 (original negative x440 and d, e, fXI,125 (original negative X300).
H samples exhibited an increased number of nuclei in a central position resembling myotubes (f ).
Electronmicroscopically (Fig. 5) , skeletal muscle samples from MCK-L animals were morphologically identical to control animals (a and d) at 5 mo of age. In contrast, MCK-M samples at this stage exhibited a most obvious increase in the number of mitochondria in the subsarcolemmic, perinuclear, and intermyofibrillar position of muscle fibers (b and e). Only very moderately increased glycogen deposition was found in vesicles or diffusely dispersed in the sarcoplasma of MCK-M samples. In skeletal muscle specimens of MCK-H animals the number of vital mitochondria was only moderately increased, but many residual mitochondria which had undergone cystic degenerative changes were detected between membranous degenerative material (c and f). In contrast to MCK-M, massive glycogen storage was observed in MCK-H samples in the sarcoplasma. These granules were partly dispersed between myofibrills and partly surrounded by membranes. Glycogen deposits were also detected in nuclear inclusions which were surrounded by invaginations of nuclear membranes (c). In summary these morphological studies show that the onset and degree of myopathic changes in skeletal muscle tissue was strongly correlated to the degree of LPL overexpression in all transgenic lines.
Cross sections of the heart were also investigated by light and electron microscopy. In MCK-M, and to a higher degree in MCK-H, an increased number of mitochondria was found in myocytes. However, only slight to moderate myopathic changes could be observed (not shown). LPL overexpression in transgenic mice had no effect on the morphology of all other organs analyzed including liver, spleen, kidney, adrenal glands, brain, lungs, and gastrointestinal as well as urogenital tracts.
Effects on the biogenesis of mitochondria and peroxisomes. As described in the preceeding section, increased LPL expression in skeletal muscle caused a drastic increase in the number of mitochondria in muscle cells of MCK-M animals. This increase was detected by electron microscopy, but also in toluidine blue-stained semithin sections and by histochemistry with NADH-tetrazolium-reductase and Gomori trichrome stainings (24, 25) . As judged from morphologic examinations, a five-to eightfold increase in the number of mitochondria was estimated in MCK-M animals compared to control animals. This morphologic finding was also confirmed by biochemical analyses of succinate dehydrogenase activity, a marker enzyme of mitochondria, which was found to be increased two-to threefold in skeletal muscle samples of MCK-M mice (Table Ill) . The degree of mitochondrial proliferation was consistently more pronounced in morphological examinations compared to the enzyme assay. As judged from electron microscopy, the number of mitochondria in muscle samples from MCK-H animals, the line with highest LPL expression, was found to be only slightly increased compared to control animals, but much lower than in skeletal muscle of MCK-M animals. This difference was not found in the activity of the mitochondrial marker enzyme succinate dehydrogenase, which was identical in muscle specimens from MCK-M and MCK-H animals (Table III) .
The effects of muscle-specific overexpression of LPL on peroxisome proliferation was investigated by electron microscopy and by determining the activity of catalase, a peroxisomal marker enzyme. The number of peroxisomes was extremely low in skeletal muscle specimens of control animals. There were only one or fewer peroxisomes per microscopic field (Fig.  6 A) . In contrast, specimens from MCK-M (b) animals and MCK-H (c) animals had between four and six peroxisomes per microscopic field, indicating a striking increase in the number of peroxisomes (Fig. 6 b and c) . Catalase activity was increased fourfold in skeletal muscle of MCK-L animals and eightfold in 982 Levak-Frank et al. both MCK-M and MCK-H animals, confirming the morphological results (Table HI) . The observation that catalase activity was similar in MCK-M and MCK-H animals, suggests that there is some upper limit to the peroxisome induction by muscle LPL expression. Catalase activity in the liver of transgenic animals was not increased compared to normal mouse liver indicating that the increase in peroxisomes was muscle specific (not shown).
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Discussion
Overexpression of human LPL in skeletal and cardiac muscle of transgenic mice resulted in major alterations of the lipid and energy metabolism of the animals. The increase in lipolytic activity was much more pronounced in skeletal muscle than in heart muscle. Increased lipolysis by LPL resulted in increased intracellular FFA levels. This was associated with weight loss and premature death. The animals developed a severe myopathy characterized by the proliferation of mitochondria and peroxisomes, glycogen storage, lymphocyte infiltration, fiber atrophy, fiber degeneration, and centralized nuclei. These various findings were solely dependent on the level and duration of LPL overexpression in muscle tissue.
In the plasma compartment increased LPL activity in muscle caused a dose-dependent reduction of the triglyceride concentrations, which was mainly due to a reduction of VLDL. Unexpectedly, the plasma concentration of FFA were not increased with increased LPL activity in transgenic mice. Low plasma FFA concentrations and, presumably, FFA transport rates to the liver were also reflected by the unchanged plasma ketone body concentrations in transgenic animals. This suggests that the majority of EFA are directly taken up by muscle tissue without entering the plasma pool. In fact, intracellular FFA concentrations were found to be increased in skeletal muscle tissue of transgenic mice in proportion to the level of LPL overexpression. It has been suggested that the cellular uptake of FFA is facilitated by two types of mechanisms, lateral movement of FFA over the cell membrane followed by the direct cellular uptake (26) , or specific FFA transport protein-mediated uptake (27, 28). Several candidate proteins have been identified from different tissues in the past including a 40-kD protein and the fatty acid transporter protein (29) (30) (31) (32) . To date, however, characterization Figure 6 . Peroxisome-specific staining in skeletal muscle specimens. Electron microscopy of skeletal muscle specimens after cytochemical staining for catalase activity using diaminobenzidine. Displayed pictures represent noncontrasted sections. In only a few microscopic fields a single peroxisome (arrows) was visualized in control animals (a). In MCK-M (b) animals and MCK-H (c) animals between four and six peroxisomes were observed in each microscopic field. Bar represents 1 gm. of these proteins remains incomplete and a detailed understanding of FFA transport through the plasma membrane has not been achieved. Our study suggests that FFA transport through the endothelial cell layer and the sarcolemmic membrane does not represent an important regulatory step because LPL-driven FFA uptake can increase intracellular FFA levels to the extent that severe myopathy and premature death results. The increase of intracellular FFA levels without an increase in plasma levels suggests that triglyceride hydrolysis and FFA uptake are tightly coupled in muscle. Consequently, the increased formation of FFA albumin complexes and their transport to the liver does not occur. Our results indicate that LPL represents the ratelimiting step in the cellular uptake of triglyceride-derived FFA fulfilling a "gate keeping function" in muscle tissue.
The increased flux of FFA into skeletal muscle tissue through LPL overexpression had a pronounced effect on body weight and body composition in transgenic animals. The animals suffered from retarded growth and weight loss due to the loss of muscle mass as well as adipose tissue mass. We presume that the excessive supply of FFA in muscle tissue caused a muscle disorder which led to the premature death of the animals. The average life span was strictly correlated with the level of LPL overexpression in muscle tissue. Morphological examinations (summarized in Table HI) revealed that the transgenic animals suffered from a condition similar to certain myopathies observed in humans. All other organs besides muscle were unaffected. The early stage of the myopathy was mainly characterized by increased numbers of mitochondria and peroxisomes. In many respects this condition resembles human mitochondriopathy in its morphological appearance (33) . After prolonged periods of time or when high levels of LPL were expressed in muscle tissue, mitochondriopathy developed into myopathy with severe degeneration of muscle fibers and large deposits of glycogen. Fiber degeneration and the appearance of large numbers of macrophages as a sign of progressive myopathy were accompanied by chronic inflammatory infiltration of the endomysium. Morphologically these phenomena closely resemble progressive or dystrophic human myopathies (24, 25) . Long chains of centralized nuclei within a high percentage of muscle fibers in this myopathy mimicks the human centronuclear (myotubular) myopathy (34) (35) (36) . However, nuclei in a centralized position are somewhat nonspecific and are found in several myopathies including neurogenic muscle disease (24, 25) . Glycogen storage in the sarcoplasma of the animals is most likely caused by the mitochondriopathy with secondary glycogen storage as is also observed in humans (24) . Excessive glycogen storage, as found in transgenic mice with the highest levels of LPL expression, is observed in patients with different forms of glycogen storage disease. These patients can develop cardiomyopathy as well as severe myopathy of the respiratory system leading to death from cardio-respiratory insufficiency (25) . We assume that the increased uptake of FFA caused by overexpression of LPL in skeletal and cardiac muscle leads to a similar pathological picture and eventually results in the death of these animals. Cardiac failure as the primary cause of death is unlikely because cardiac weight was found to be unchanged. Therefore, respiratory insufficiency appears to be the most likely cause of death in MCK animals.
The constellation of myopathic changes observed in transgenic mice provokes the speculation that disturbed regulation of extracellular lipolysis or increased uptake of PFA might also be causally involved in the pathogenesis of human myopa- (46) . Additionally it was demonstrated that the OLE1 gene in yeast encoding a fatty acid desaturase, is essential for the movement and the inheritance of mitochondria (47) . Our experiments support the concept that FFA represent signal-transducing molecules (48) (49) (50) and suggest an important role for FFA in the biogenesis of mitochondria in mammals.
Transgenic animals overexpressing human LPL have been generated and characterized in several previous studies (51) (52) (53) . Our results are in agreement with the effect of LPL overexpression on plasma triglyceride levels. However, the observed dramatic effects on body weight, body composition, muscle morphology, and metabolism have not been reported in the previous studies. This could be explained by the different sites and levels of LPL expression in the different transgenic mouse models. In contrast to our approach of tissue-specific LPL overexpression, all other studies used tissue nonspecific expression systems. Under these conditions relatively low levels of LPL expression were detected in many tissues of the body. Therefore, the partitioning of EFA among essentially all tissues in the body and the low level of muscle lipolysis may have precluded seeing the myopathic effects observed in our study. In one report (53) , a high perinatal mortality was reported presumably caused by the tissue nonspecific overexpression of the LPL gene under the control of a metallothionein promoter. These observations were not made in our system of muscle-specific LPL overexpression.
In conclusion our results indicate that LPL represents the rate-limiting step for the cellular uptake of triglyceride-derived FFA. FFA transport through the endothelial cell layer and the sarcolemmic membrane apparently does not have such a regulatory function. Excessive FFA uptake in muscle by increased LPL activity can cause major pathologic changes including the proliferation of mitochondria and peroxisomes and the development of a lipolysis-induced myopathy.
